Intrahepatic and intravenous administration of adriamycin—A Comparative pharmacokinetic study in patients with malignant liver tumours

Ignoffo R J, Øie S, Friedman M A: Pharmacokinetics of methotrexate administered via the hepatic artery.Cancer Chemother Pharmacol 5, 217 (1981).

Mattsson W, Jonsson K, Hellekant C, Hallsten L: Short-term intra-arterial Mitomycin C in hepatic metastases.Acta radiol 19, 321 (1980).

Buchwald H, Grage T B, Vassilopoulos P P, Rohde T D, Varco R L, Blackshear P L: Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump.Cancer 45, 866 (1980).

Ensminger W D, Rosowsky A, Raso V, Levin D C, Glode M, Come S, Steele G, Frei E III: A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil.Cancer Res 38, 3784 (1978).

Lee Y-T N, Irwin L: Hepatic artery ligation and adriamycin infusion chemotherapy for hepatoma.Cancer 41, 1249 (1978).

Lee Y-T N, Chan K K, Harris P A, Cohen J L: Distribution of adriamycin in cancer patients. Tissue uptakes, plasma concentration after IV and hepatic IA administration.Cancer 45, 2231 (1980).

Bern M M, McDermott W Jr, Cady B, Oberfield R A, Trey C, Clouse M E, Tullis J L, Parker L M: Intraarterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma. A clinical and pharmacology report.Cancer 42, 399 (1978).

Garnick M B, Ensminger W D, Israel M: A clinical-pharmacological evaluation of hepatic arterial infusion of adriamycin.Cancer Res 39, 4105 (1979).

Chlebowski R T, Chan K K, Tong M J, Weiner J M, Ryden V M J, Bateman J R: Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma. Clinical and pharmacokinetic aspects.Cancer 48, 1088 (1981).

Eksborg S, Ehrsson H, Wallin I, Lindfors A: Quantitative determination of adriamycin and daunorubicin —handling of blood and plasma samples.Acta pharm suec 18, 215 (1981).

Eksborg S, Ehrsson H, Andersson I: Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol.J Chromatogr 164, 479 (1979).

Gibaldi M, Perrier D:Pharmacokinetics. New York, Marcel Dekker (1975).

Eckman W W, Patlak C S, Fenstermacher J D: A critical evaluation of the principles governing the advantages of intraaterial infusions.J Pharmacokinet Biopharmac 2, 257 (1974).

Chen H S G, Gross J F: Intraarterial infusion of anti-cancer drugs: theoretic aspects of drug delivery and review of responses.Cancer Treat Rep 64, 31 (1980).

Benjamin R S: Clinical pharmacology of adriamycin (NSC-123127).Cancer Chemother Rep Part 3 6, 183 (1975).

Benjamin R S, Riggs C E Jr, Bachur N R: Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function.Cancer Res 37, 1416 (1977).

Ehninger G, Stocker H-J, Proksch B, Wilms K: Die Pharmakokinetik von Adriamycin und Adriamycin-Metaboliten.Klin Wochenschr 58, 927 (1980).

Legha S S, Benjamin R S, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen S L, Blumenschein G R, Freireich E J: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.Ann intern Med 96, 133 (1982).

Weiss A J, Metter G E, Fletcher W S, Wilson W L, Grage T B, Ramirez G: Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity.Cancer Treat Rep 60, 813 (1976).

Benjamin R S: A practical approach to adriamycin (NSC-123127) toxicology.Cancer Chemother Rep Part 3 6, 191 (1975).

Breedis C, Young G: The blood supply of neoplasms in the liver.Am J Path 30, 969 (1954).

Benjamin R S, Wiernik P H, Bachur N R: Adriamycin chemotherapy—efficacy, safety and pharmacologic basis for an intermittent single high-dosage schedule.Cancer 33, 19 (1974).

Erlichman C, Donehower R C, Chabner B A: The practical benefits of pharmacokinetics in the use of antineoplastic agents.Cancer Chemother Pharmacol 4, 139 (1980).

Chan K K, Chlebowski R T, Tong M, Chen H-S G, Gross J F, Bateman J R: Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis.Cancer Res 40, 1263 (1980).

Eksborg S, Ehrsson H, Ekqvist B: Protein binding of anthraquinone glycosides, with special reference to adriamycin.Cancer Chemother Pharmacol 10, 7 (1982).

Bachur N R: Adriamycin pharmacology.Cancer Chemother Rep 3, 153 (1975).